Efficacy and safety of neoadjuvant immunotherapy in locally advanced resectable esophageal squamous cell carcinoma: a network meta-analysis and real-world study - PubMed
5 hours ago
- #immunotherapy
- #esophageal squamous cell carcinoma
- #neoadjuvant therapy
- Study explores efficacy and safety of neoadjuvant immunotherapy in locally advanced resectable esophageal squamous cell carcinoma (ESCC).
- Network meta-analysis (NMA) and real-world study (RWS) methods were used to evaluate different immunotherapy regimens.
- Sintilimab plus chemoradiotherapy showed the highest pathological complete response (pCR) rate.
- Camrelizumab plus nab-paclitaxel/platinum performed best in major pathological response (MPR) and R0 resection rates.
- Sintilimab plus nab-paclitaxel/platinum had the lowest adverse event (AE) incidence.
- Real-world data indicated a higher MPR rate in the Camrelizumab group compared to Tislelizumab (46.9% vs 12.5%).
- MPR and primary tumor T response were identified as independent protective factors for overall survival (OS) and progression-free survival (PFS).
- Neoadjuvant radiotherapy correlated with poorer OS and PFS.
- The study concludes that neoadjuvant immunotherapy combinations, especially Cam+nab-TP, show favorable efficacy in ESCC.
- MPR serves as a reliable surrogate endpoint for long-term survival.